Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 224

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 224
---
 are the cash flows, including the success rates:

From the Pre-Tax Income, taxes at a rate of 26.5% (US, Florida company tax rate) were deducted. The net income resulting was then discounted at a rate of 30% and a terminal value rate of 2%. Following is a concise DCF that includes the tax expenses and is discounted by the WACC:

Under all the above assumptions, the company’s value is $101,093 thousand (Rounded to $101 million).

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 22 of 24 |

Appendix – Benchmark Drugs and Treatments

Following are the explanations of our choices for the Drugs and Treatments benchmarks used in the valuation.

AMD

The chosen benchmark used for the price of the AMD treatment is based on two existing drugs that were recently approved by the FDA for the treatment of late-stage AMD (Geographical Atrophy – GA).

Syfovre (by Apellis) 14:

Syfovre is an eye injection designed to slow the progression of the disease that is administered once every 25 to 60 days. With the FDA approval, it’s become the first and only treatment for the debilitating condition. The vision loss caused by geographic atrophy has a severely negative impact on quality of life.

Apellis notes that Syfovre is not a cure. The drug’s approval was based on its ability to slow the growth of geographic atrophy lesions, a marker of the disease, without any impact on slowing disease progression or the progression of central vision loss.

Syfovre is a C3 therapy designed to regulate the over-activation of the complement cascade, which is an important part of the immune system. In geographic atrophy, excessive complement activation causes the destruction of retinal cells through irreversible lesion growth. C3 has been found to be the only target that can modulate the complement cascade because of its central location in the cascade.

Apellis revealed the list price of Syfovre to be $2,190 per vialbefore discounts and said it would be made available through specialty distributors and pharmacies across the US.

Izervay (by Iveric Bio, a company of Astella) 15:

Iveric Bio, a company of Astellas, has secured recent approval from the US Food and Drug Administration (FDA) for its innovative drug, Izervay (avacincaptad pegol intravitreal solution). This major achievement now allows